drugset / Trial / NCT02944383

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

NCT02944383

Phase 2 Completed 91 enrolled NeuroBo Pharmaceuticals Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)

Timeline

Start
2016-12
Primary completion
2018-01-11
Completion
2018-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcabene Small molecule 300 mg Oral
Subject Gemcabene Small molecule 600 mg Oral